Skip to main content
. 2017 Sep 19;117(10):1486–1494. doi: 10.1038/bjc.2017.325

Table 1. Demographics and clinical variables of the participants.

Variable No. (%) The intervention group (IG, n=95) Loss of follow up (n=13) P-value The control group (CG, n=85) Loss of follow up (n=19) P-value P-value (IG vs CG)
Age     0.0642     0.8675 0.4451
 ⩽40 26 (27.4) 2 (15.4)   24 (28.2) 5 (26.4)    
 >40 and ⩽60 47 (49.5) 4 (30.8)   35 (41.2) 7 (36.8)    
 >60 22 (23.1) 7 (53.8)   26 (30.6) 7 (36.8)    
Race     <0.001     0.0440 0.2831
 Han 90 (94.7) 7 (53.8)   77 (90.6) 14 (73.7)    
 Other 5 (5.3) 6 (46.2)   8 (9.4) 5 (26.3)    
Education     0.7481     0.5644 0.3185
 High school or lower 54 (56.8) 8 (61.5)   42 (49.4) 8 (42.1)    
 Undergraduate or higher 41 (43.2) 5 (38.5)   43 (50.6) 11 (57.9)    
Income (monthly)     0.3828     0.5364 0.0254
 ⩽¥5000 37 (38.9) 7 (53.8)   34 (40.0) 8 (42.1)    
 >¥5000 and ⩽¥10 000 41 (43.2) 3 (23.1)   23 (27.1) 7 (36.8)    
 >¥10 000 17 (17.9) 3 (23.1)   28 (32.9) 4 (21.1)    
Relationship     <0.001     0.1331 0.3200
 Single 6 (6.3) 4 (30.8)   9 (10.6) 2 (10.5)    
 Married 81 (85.3) 4 (30.8)   65 (76.5) 11 (57.9)    
 Divorced or widowed 8 (8.4) 5 (38.4)   11 (12.9) 6 (31.6)    
Religious affiliation     0.0360     <0.001 0.1335
 Yes 19 (20.0) 6 (46.2)   10 (11.8) 11 (57.9)    
 No 76 (80.0) 7 (53.8)   75 (88.2) 8 (42.1)    
Employment     0.1212     0.0528 0.1789
 Part/full time 37 (38.9) 8 (61.5)   25 (29.4) 10 (52.6)    
 Unemployed 58 (61.1) 5 (38.5)   60 (70.6) 9 (47.4)    
Menopausal status     0.4873     0.4478 0.1030
 Premenopausal or perimenopausal 74 (77.9) 9 (69.2)   57 (67.1) 11 (57.9)    
 Postmenopausal 21 (22.1) 4 (30.8)   28 (32.9) 8 (42.1)    
Type of surgery     0.3617     0.0467 0.3843
 Mastectomy 54 (56.8) 5 (38.5)   42 (49.4) 7 (36.8)    
 Lumpectomy 32 (33.7) 7 (53.8)   37 (43.5) 7 (36.8)    
 Other 9 (9.5) 1 (7.7)   6 (7.1) 5 (26.4)    
Chemotherapy     0.4285     0.4698 0.7540
 Ever 59 (62.1) 5 (38.5)   47 (49.5) 8 (42.1)    
 Current 67 (70.5) 9 (69.2)   58 (68.2) 14 (73.7)    
Hormone therapy     0.9160     0.7539 0.7542
 Ever 56 (58.9) 5 (38.5)   54 (63.5) 12 (63.2)    
 Current 31 (32.6) 3 (23.1)   27 (31.8) 5 (26.3)    
Radiation therapy     0.7484     0.3421 0.7737
 Ever 40 (42.1) 5 (38.5)   44 (51.8) 8 (42.1)    
 Current 12 (12.6) 2 (15.4)   15 (17.6) 5 (26.3)    
Oestrogen-receptor status     0.2280     0.1208 0.3933
 Positive or equivocal 53 (55.8) 4 (30.8)   53 (62.4) 7 (36.8)    
 Negative 31 (32.6) 7 (53.8)   20 (23.5) 8 (42.1)    
 Unknown 11 (11.6) 2 (15.4)   12 (14.1) 4 (21.1)    
Sites of metastases     0.0133     0.7913 0.4736
 Any visceral 32 (33.7) 9 (69.2)   33 (38.8) 8 (42.1)    
 Nonvisceral only 63 (66.3) 4 (30.8)   52 (61.2) 11 (57.9)    
ECOG performance status     0.0098     0.0950 0.8105
 0 35 (36.8) 3 (23.1)   35 (41.2) 8 (42.1)    
 1 48 (50.5) 4 (30.7)   39 (45.9) 5 (26.3)    
 2 12 (12.6) 6 (46.2)   11 (12.9) 6 (31.6)    
Estimated survival     0.8378     0.1448 0.9867
 6–12 months 23 (24.2) 3 (23.0)   21 (24.7) 7 (36.8)    
 12–24 moths 43 (45.3) 5 (38.5)   39 (45.9) 4 (21.1)    
 >24 months 29 (30.5) 5 (38.5)   25 (29.4) 8 (42.1)